American Century Companies
PRQR icon

American Century Companies’s ProQR Therapeutics PRQR Stock Holding History

American Century Companies’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,686
Closed -$103K – 2922
2025
Q1 		$103K Sell
77,686
-11,841
-13% -$25.2K ﹤0.01% 2825
2024
Q4 		$237K Buy
+89,527
New +$284K ﹤0.01% 2747

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

American Century Companies's PRQR Position: Q2 2025 in Review

American Century Companies sold out of ProQR Therapeutics (PRQR) in Q2 2025, closing a stake of 77,686 shares — an estimated $103K sold.

American Century Companies first reported a position in PRQR in Q4 2024 and held it in 2 quarters. The position peaked at $237K in Q4 2024. 62 funds tracked by Wall St. Rank hold PRQR as of Q2 2025.

  • American Century Companies reported no remaining ProQR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • American Century Companies sold 77,686 ProQR Therapeutics shares in Q2 2025, an estimated $103K.
  • American Century Companies first reported a position in ProQR Therapeutics in Q4 2024 and held it in 2 quarters.
  • American Century Companies's ProQR Therapeutics position peaked at $237K in Q4 2024.
  • 62 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2025.

Based on American Century Companies's 13F filing for Q2 2025, filed 12 Aug 2025.